Vimarsana
Biggest News Aggregation in the World

Serial Studies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Serial Studies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Serial Studies Today - Breaking & Trending Today

Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai's Novel RNA-based Liquid Biopsy Platform in Breast Cancer - Vimarsana News

Exai Bio and Quantum Leap Healthcare Collaborative Announce Expanded Participation in I-SPY 2 Trial to Advance Exai's Novel RNA-based Liquid Biopsy Platform in Breast Cancer

Published: March 30, 2023

/PRNewswire/ -- Exai Bio today announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to broaden the use of Exai's novel,...

Source: prnewswire.com
Related Topics:
San AntonioUnited StatesSan FranciscoLaura EssermanPat ArensdorfPrnewswire Exai BioBiomarker Working GroupDrug AdministrationUniversity Of CaliforniaQuantum Leap Healthcare CollaborativeAntonio Breast Cancer SymposiumChief Executive OfficerSerial StudiesPredict Your Therapeutic ResponseImaging AndMolecular AnalysisLeap Healthcare CollaborativeSilicon Valley
Quantum Leap Healthcare Collaborative Announce Termination of the Cyproheptadine Treatment Arm for Critically Ill COVID-19 Patients in the I-SPY COVID Trial - Vimarsana News

Quantum Leap Healthcare Collaborative Announce Termination of the Cyproheptadine Treatment Arm for Critically Ill COVID-19 Patients in the I-SPY COVID Trial

Published: January 4, 2023

/PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the cyproheptadine arm of the study has been...

Source: prnewswire.com
Related Topics:
United StatesSan FranciscoSara AuldJohn KazianisLaura EssermanUniversity Of CaliforniaDepartment Of Defense DoProgram Executive OfficeDepartment Of DefenseBiomedical Advanced ResearchWorld Health OrganizationData Monitoring CommitteeDevelopment AuthorityInternational PartnersTrial Biomarker Working GroupDefense ConsortiumDefense Threat Reduction AgencyLeap Healthcare CollaborativeFady YoussefBiomarker Working GroupAssistant SecretaryJoint Program Executive OfficeQuantum Leap Healthcare CollaborativeSilicon ValleyMass Destruction
Quantum Leap Healthcare Collaborative Announces Termination of the Cyclosporine Treatment Arm for Critically Ill COVID-19 Patients in the I-SPY COVID Trial - Vimarsana News

Quantum Leap Healthcare Collaborative Announces Termination of the Cyclosporine Treatment Arm for Critically Ill COVID-19 Patients in the I-SPY COVID Trial

Published: August 8, 2022

/PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announces that the cyclosporine arm of the study has been...

Source: prnewswire.com
Related Topics:
United StatesSan FranciscoAngela HaczkuJacqueline MurrayLaura EssermanCarolyn CalfeeUniversity Of CaliforniaUs Department Of HealthHuman ServicesBiomedical Advanced ResearchWorld Health OrganizationData Monitoring CommitteeDevelopment AuthorityTrial Biomarker Working GroupNuclear DefenseDefense ConsortiumDefense Threat Reduction AgencyLeap Healthcare CollaborativeSari MoskowitzBiomarker Working GroupStratefgic PreparednessJoint Program Executive OfficeQuantum Leap Healthcare CollaborativeSilicon ValleySerial Studies
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) When Given by Mouth Inhalation in Critically Ill P... - Vimarsana News

I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Suggests No Clinical Benefit with Addition of Nebulized ZYESAMI® (aviptadil) When Given by Mouth Inhalation in Critically Ill P...

Published: March 31, 2022

SAN FRANCISCO, March 31, 2022 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announced in collaboration with NRx Pharmaceuticals, In...

Source: businessinsider.com
Related Topics:
United StatesSan FranciscoUniversity Of CaliforniaNational Institutes Of HealthWorld Health OrganizationDrug AdministrationData Monitoring CommitteeNrx Pharmaceuticals IncNrx PharmaceuticalsNrxp Nrx PharmaceuticalsUs National Institutes Of HealthQuantum Leap Healthcare CollaborativeHuman Vasoactive Intestinal PolypeptideNational InstitutesHigh Flow Nasal CannulaMechanical VentilationSilicon ValleyFast TrackBreakthrough TherapySpecial Protocol AgreementBiomarker LetterSerial StudiesPredict YourBiomarker IntegrationAdaptive Learning
No Clinical Benefit Suggested by Addition of Pulmozyme® to Treatment of Critically Ill Patients With COVID-19 in I-SPY COVID Trial - Vimarsana News

No Clinical Benefit Suggested by Addition of Pulmozyme® to Treatment of Critically Ill Patients With COVID-19 in I-SPY COVID Trial

Published: January 10, 2022

/PRNewswire/ -- Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the Pulmozyme® (dornase alfa) arm of the...

Source: prnewswire.com
Related Topics:
United StatesSan FranciscoLaura EssermanJon KoffCarolyn CalfeeUniversity Of CaliforniaUs Department Of HealthHuman ServicesBiomedical Advanced ResearchWorld Health OrganizationData Monitoring CommitteeDevelopment AuthorityTrial Biomarker Working GroupRoche GroupNuclear DefenseDefense ConsortiumDefense Threat Reduction AgencyToday Quantum Leap Healthcare CollaborativeAcute Respiratory Distress SyndromeBiomarker Working GroupUnited States GovernmentAssistant SecretaryJoint Program Executive OfficeQuantum Leap Healthcare CollaborativeSilicon Valley